FDA Approves Daybue, the First Treatment for Rett Syndrome

TUESDAY, March 14, 2023 – The U.S. Food and Drug Administration has approved Daybue (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients aged 2 years and older.

Approval was based on results from the phase 3...